| Literature DB >> 22191076 |
Jennifer L McGinley1, Clarissa Martin, Frances E Huxham, Hylton B Menz, Mary Danoudis, Anna T Murphy, Jennifer J Watts, Robert Iansek, Meg E Morris.
Abstract
Both efficacy and clinical feasibility deserve consideration in translation of research outcomes. This study evaluated the feasibility of rehabilitation programs within the context of a large randomized controlled trial of physical therapy. Ambulant participants with Parkinson's disease (PD) (n = 210) were randomized into three groups: (1) progressive strength training (PST); (2) movement strategy training (MST); or (3) control ("life skills"). PST and MST included fall prevention education. Feasibility was evaluated in terms of safety, retention, adherence, and compliance measures. Time to first fall during the intervention phase did not differ across groups, and adverse effects were minimal. Retention was high; only eight participants withdrew during or after the intervention phase. Strong adherence (attendance >80%) did not differ between groups (P = .435). Compliance in the therapy groups was high. All three programs proved feasible, suggesting they may be safely implemented for people with PD in community-based clinical practice.Entities:
Year: 2011 PMID: 22191076 PMCID: PMC3236432 DOI: 10.1155/2012/795294
Source DB: PubMed Journal: Parkinsons Dis ISSN: 2042-0080
Safety during the intervention phase.
| PST | MST | LS | |
|---|---|---|---|
| “New soreness > 48 hrs.” | |||
| Occasions of new soreness ( | 25 | 11 | 0 |
| Participants reporting new soreness ( | 18 | 10 | 0 |
|
| |||
| Incidents during therapy sessions | 1 (fall; no sequelae) | 2 (dizziness; no sequelae) | 0 |
|
| |||
| Falls during intervention phase | |||
| Number of fallers ( | 10 | 24 | 24 |
| Falls frequency: median (IQR) | 0 (0) | 0 (0-1) | 0 (0-1) |
| Falls frequency: range ( | 0–7 | 0–24 | 0–52 |
| Median time to first fall (days) | 14 | 9 | 9 |
Assessments attended across the course of the trial.
| Assessment | PST | MST | LS |
|---|---|---|---|
| TI (Baseline assessment) | 70 (100) | 69 (100) | 71 (100) |
| T2 (1 week after intervention phase) | 69 (98.6) | 68 (98.6) | 59 (83.1) |
| T3 (3/months after intervention phase) | 67 (95.7) | 64 (92.8) | 54 (76.1) |
| T4 (12 months after intervention phase) | 65 (92.9) | 63 (91.3) | 56 (78.9) |